menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)||Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Vemurafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Kechow Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HL-003","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Kechow Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Kechow Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai Kechow Pharma

    Menu

    Shanghai Kechow Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HL-003

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects

                            Details : HL-003 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : HL-003

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            KeChow Gets NMPA Approval for Tunlametinib as First Targeted Therapy for NRAS Melanoma

                            Details : HL-085 (tunlametinib) is a small molecule inhibitor of Mitogen-activated protein kinase. It is approved by NMPA for the treatment of NRAS Mutated Advanced Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2024

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

                            Details : Tunlametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2023

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal ...

                            Details : Tunlametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2023

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer...

                            Details : HL-085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 12, 2023

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

                            Details : HL-085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neurofibromatosis 1.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 15, 2022

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

                            Details : HL-085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 02, 2022

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

                            Details : HL-085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2022

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HL-085 in NRAS-mutated Advanced Melanoma

                            Details : HL-085 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2022

                            Lead Product(s) : Tunlametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed

                            Shanghai Kechow Pharma

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vemurafenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Roche and KeChow Reach a Cooperation Agreement

                            Details : Under this collaboration, KeChow will promote Roche's Zelboraf® in China. Zelboraf® is an oral small molecule, selective BRAF inhibitor indicated for the treatment of patients with BRAF V600 mutation-positive advanced or inoperable melanoma.

                            Product Name : Zelboraf

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 20, 2021

                            Lead Product(s) : Vemurafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth